908 Devices completes sale of desktop business to Repligen; pro forma shows $40.4M net loss from continuing ops in 2024

908 Devices Inc.

Sold desktop portfolio (Maverick, Rebel, Maven, Trace C2, ZipChip) to Repligen for ~$66M net upfront cash after transaction costs.
Estimated gain on sale of $54.7M treated as discontinued operations; pro forma net loss from continuing ops improved to $(40.4M) in 2024 from $(72.2M) historical.
Pro forma 2024 continuing ops revenue of $47.7M vs historical total $59.6M; loss per share from continuing ops $(1.19) vs historical $(2.12).
Transaction includes supply agreement and transition services; estimated bonus of $0.65M to remaining employees.
Cumulative translation adjustment of $1.1M released upon sale of 908 Devices GmbH.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.